Dr Shom Goel is a clinician-scientist at the University of Melbourne and Peter MacCallum Cancer Centre, with a strong interest in Translational Breast Cancer Research. He was a guest speaker at the 2022 Breast Cancer Trials Annual Scientific Meeting and we asked Dr Goel to explain his research in CDK4/6 inhibitors and where research is going in the future.

CDK4/6 Inhibitors - Making the Most of a Good Thing

Breast Cancer Trials is a group of world-leading breast cancer doctors and researchers based in Australia and New Zealand, with a commitment to exploring and finding better treatments for people affected by breast cancer through clinical trials research. The Breast Cancer Trials Podcast is a platform to share the latest in breast cancer research, to share stories and experiences of those who have had breast cancer, and to help explain topics around breast cancer and clinical trials research. www.breastcancertrials.org.au

Share CDK4/6 Inhibitors - Making the Most of a Good Thing

Sign up to save your podcasts

CDK4/6 Inhibitors - Making the Most of a Good Thing

CDK4/6 Inhibitors - Making the Most of a Good Thing